Company Focus
Galderma
Latest Galderma News
Biotechnology
Swiss dermatology company Galderma has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic dermatitis and prurigo nodularis. 18 February 2025
Dermatology News
Insights
Company Spotlight
Abeona Therapeutics is an Ohio-based biotech firm developing novel gene and cell therapies for the treatment of individuals with rare diseases.
Latest News & Features of interest to Galderma
Pharmaceutical
Swiss biopharma Relief Therapeutics closed Thursday’s trading 50% higher. 23 May 2025
Biosimilars
Formycon and its commercialization partner Fresenius Kabi have announced that the US Food and Drug Administration (FDA) has designated FYB202/Otulfi (ustekinumab-aauz) as interchangeable with Johnson & Johnson’s (NYSE: JNJ) reference biologic Stelara (ustekinumab). 19 May 2025
Pharmaceutical
Danish dermatology specialist LEO Pharma today released financial results for the first-quarter of 2025, noting its continued robust growth, driven by dermatology, and made significant strategic progress. 15 May 2025
Pharmaceutical
Spanish dermatology specialist Almirall was the envy of investors on Monday, with its share price closing 10% higher. 12 May 2025
Biotechnology
US healthcare giant Johnson & Johnson has announced new data from the Phase III ICONIC-TOTAL study investigating icotrokinra (JNJ-2113), the first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor. 12 May 2025
Pharmaceutical
Following a European Union-wide review of available data on finasteride and dutasteride medicines, the European Medicines Agency’s (EMA) safety committee (PRAC) has confirmed suicidal ideation (suicidal thoughts) as a side effect of finasteride 1mg and 5mg tablets but concluded that the benefits of finasteride and dutasteride medicines continue to outweigh their risks for all approved uses. 8 May 2025
Pharmaceutical
Japanese drugmaker Shionogi is to scale up its pipeline and global ambitions with a deal worth more than $1 billion, buying the pharmaceutical operations of Japan Tobacco, including its US subsidiary Akros Pharma. 8 May 2025
Biosimilars
Teva Pharmaceutical Industries’ US subsidiary and Iceland-based Alvotech (Nasdaq: ALVO) today announced that the US Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) injection as interchangeable with the reference biologic Stelara (ustekinumab). 5 May 2025
Biotechnology
The global dermatological cell and gene therapy (CGT) market is poised for exceptional growth at a compound annual growth rate (CAGR) of 31.3%, with sales projected to rise from $291 million in 2024 to $1.5 billion in 2030. 2 May 2025
Biotechnology
The US Food and Drug Administration (FDA) has approved Zevaskyn (prademagene zamikeracel) gene-modified cellular sheets, also known as pz-cel, from US gene therapy developer Abeona Therapeutics. 30 April 2025
Latest In Brief for Galderma
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Latest Dermatology Ones To Watch News
Japanese drugmaker Shionogi is to scale up its pipeline and global ambitions with a deal worth more than $1 billion, buying the pharmaceutical operations of Japan Tobacco, including its US subsidiary Akros Pharma. 8 May 2025
21 February 2025
4 October 2024
18 September 2024
Dermatology Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze